Transcriptomics analysis and benchmark concentration estimating-based in vitro test with IOSE80 cells to unveil the mode of action for female reproductive toxicity of bisphenol A at human-relevant levels

Li, Yongming; Xiong, Wei; Lin, Tao; Yang, Zhao; Zhang, Lishi; Chen, Jinyao

doi:10.1016/j.ecoenv.2022.113523

Cited by 7 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 A decrease in CDKN3 promoted G1 phase cell cycle arrest, 15,20,47 which might be due to decreasing the expression of CDK2, 10 while an increase in CDKN3 significantly facilitated G1/S transition, S phase arrest, and G2/M transition. 9,11,[48][49][50][51][52] In this paper, the in vitro experiment showed that CDKN3 significantly facilitated the G1/S transition. CDKN3 has also been found to regulate the cell cycle-associated proteins cyclin D1, CDK4, pAKT, P27, P53 and P21.…”

mentioning

confidence: 74%

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Gao,

Fan,

Liu

et al. 2023

IJGM

View full text Add to dashboard Cite

Background: Cyclin-dependent kinase inhibitor 3 (CDKN3) has been studied in many cancers. However, the comprehensive and systematic pancancer analysis of CDKN3 genes is still lacking. Methods: Data were downloaded from online databases. R was used for analysis of the differential expression and gene alteration of CDKN3 and of the associations between CDKN3 expression and survival, signaling pathways, and drug sensitivity. Clinical samples and in vitro experiments were selected for verification. Results: CDKN3 expression was higher in most types of cancers, and this phenotype was significantly correlated with poor survival. CDKN3 showed gene alterations and copy number alterations in many cancers and associated with some immune-related pathways and factors. Drug sensitivity analysis elucidated that CDKN3 could be a useful marker for therapy selection. Clinical samples elucidated CDKN3 expressed high in endometrial cancer tissue. In vitro studies showed that CDKN3 induced pro-tumor effect in immune environment and facilitated endometrial cancer cell proliferation and G1/S phase transition. Conclusion: CDKN3 has been shown to be highly expressed in most types of cancers and promoted cancer cell progression. CDKN3 may serve as a novel marker in clinical diagnosis, treatment, and prognosis prediction in future.

show abstract

mentioning

confidence: 74%

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Gao,

Fan,

Liu

et al. 2023

IJGM

View full text Add to dashboard Cite

show abstract

“…As BPA concentrations escalated, the presence of the ERK inhibitor U0126 elicited a modest reduction in protein expression of ERK, concurrent with alterations in relative mRNA levels and Cyclin-dependent kinase inhibitor 3 (CDKN3). Consequently, a diminished ratio of cells in the S phase and G0/G1 phase signaled impediments in cellular progression through these specific phases of the cell cycle, underscoring the intricate consequences of BPA on female reproductive biology [ 44 ].…”

Section: Bpa-induced Organ Toxicitymentioning

confidence: 99%

Deciphering the molecular mechanism of NLRP3 in BPA-mediated toxicity: Implications for targeted therapies

Charles,

Prince

2024

Heliyon

View full text Add to dashboard Cite

“…Additionally, it interacts with phosphatase KAP, exerting regulatory control over cell cycle progression [6][7][8][9]. As a crucial factor in cellular regulation, CDKN3 has been demonstrated to promote matrix degradation and inflammatory response in coronary artery endothelial cells [10][11][12]. Recently several studies reported that CDKN3 played a important role in the inflammatory response observed in severe cases of COVID-19 [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Human pan-cancer analysis of the predictive biomarker for the CDKN3

Chen,

Li,

Sha

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background Cell cycle protein-dependent kinase inhibitor protein 3 (CDKN3), as a member of the protein kinase family, has been demonstrated to exhibit oncogenic properties in several tumors. However, there are no pan-carcinogenic analyses for CDKN3. Methods Using bioinformatics tools such as The Cancer Genome Atlas (TCGA) and the UCSC Xena database, a comprehensive pan-cancer analysis of CDKN3 was conducted. The inverstigation encompassed the examination of CDKN3 function actoss 33 different kinds of tumors, as well as the exploration of gene expressions, survival prognosis status, clinical significance, DNA methylation, immune infiltration, and associated signal pathways. Results CDKN3 was significantly upregulated in most of tumors and correlated with overall survival (OS) of patients. Methylation levels of CDKN3 differed significantly between tumors and normal tissues. In addition, infiltration of CD4 + T cells, cancer-associated fibroblasts, macrophages, and endothelial cells were associated with CDKN3 expression in various tumors. Mechanistically, CDKN3 was associated with P53, PI3K-AKT, cell cycle checkpoints, mitotic spindle checkpoint, and chromosome maintenance. Conclusion Our pan-cancer analysis conducted in the study provides a comprehensive understanding of the involvement of CDKN3 gene in tumorigenesis. The findings suggest that targeting CDKN3 may potentially lead to novel therapeutic strategies for the treatment of tumors.

show abstract

Transcriptomics analysis and benchmark concentration estimating-based in vitro test with IOSE80 cells to unveil the mode of action for female reproductive toxicity of bisphenol A at human-relevant levels

Cited by 7 publications

References 34 publications

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Deciphering the molecular mechanism of NLRP3 in BPA-mediated toxicity: Implications for targeted therapies

Human pan-cancer analysis of the predictive biomarker for the CDKN3

Contact Info

Product

Resources

About